Literature DB >> 2907458

In vivo radical trapping and biliary secretion of radical adducts of carbon tetrachloride-derived free radical metabolites.

K T Knecht1, R P Mason.   

Abstract

Products of the well documented reductive metabolism of CCl4 to .CCl3 have been examined by free radical trapping and ESR in vivo. We have found the phenyl-N-t-butylnitrone (PBN) radical adduct of .CCl3 in the bile of rats treated with the radical trap and 13CCl4. Hypoxia or pretreatment with phenobarbital has been reported to enhance the hepatotoxicity of CCl4 in vivo; these treatments also produced an increase in the biliary concentration of the PBN/.CCl3 radical adduct and in the .CCl3-derived PBN/.CO(-)2 radical adduct as well. A 13C-invariant spectrum detected upon PBN administration, with or without carbon tetrachloride, may be due to a lipid-derived species. ESR analysis of bile from animals treated with free radical traps and xenobiotics may prove useful in monitoring hepatic free radical-adduct formation in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2907458

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

Review 1.  Measurements in vivo of parameters pertinent to ROS/RNS using EPR spectroscopy.

Authors:  Nadeem Khan; Harold Swartz
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

2.  The role of the liver in the production of free radicals during halothane anaesthesia in the rat. Quantification of N-tert-butyl-alpha-(4- nitrophenyl)nitrone (PBN)-trapped adducts in bile from halothane as compared with carbon tetrachloride.

Authors:  H M Hughes; I M George; J C Evans; C C Rowlands; G M Powell; C G Curtis
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

3.  Direct evidence for in vivo hydroxyl-radical generation in experimental iron overload: an ESR spin-trapping investigation.

Authors:  M J Burkitt; R P Mason
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.